QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
QLMA-EC-IIT-001
Phase 2 small_molecule active
Quick answer
QL1706 (bispecific antibody targeting PD-1 and CLTA-4) for Esophageal Squamous Cell Carcinoma (ESCC) is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Esophageal Squamous Cell Carcinoma (ESCC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active